D-glucose is an investigational drug.
There have been 48 clinical trials for D-glucose.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2021.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), University of Pennsylvania, and M.D. Anderson Cancer Center.
There are thirteen US patents protecting this investigational drug and six hundred and fifty-one international patents.